1 / 2
Tirzepatide CAS 2023788-19-2 API
GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids.
$220.00 /g
(Min.Order 1g)
Product Details
| Product | Tirzepatide |
| CAS No | 2023788-19-2 |
| Molecular Formula |
C225H348N48O68
|
| Molecular Structural Formula |
|
| Molecular Weight | 4813.45 |
| Indication | Obesity, Type ll Diabetes. |
| Pharmacology | GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. |
| Route of administration | subcutaneous injection |
| Taboo | Tirzepatide is not suitable for patients with medullary thyroid cancer |
| Amino Acid Sequence | Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-lle-{Aib}Leu-Asp-Lys-lle-Ala-GIn-{diacid-C20-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-GIn-Trp-Leu-lle-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Solubility | Soluble in water |
| purity | ≥99% |